Wedbush Has Positive Forecast for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Analysts at Wedbush upped their FY2024 earnings per share estimates for Compass Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.32) for the year, up from their previous forecast of ($0.39). Wedbush currently has a "Outperform" rating and a $8.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.42) per share. Wedbush also issued estimates for Compass Therapeutics' Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at $0.31 EPS and FY2028 earnings at $1.76 EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03.

A number of other equities analysts also recently issued reports on CMPX. Leerink Partners downgraded Compass Therapeutics from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $5.00 to $4.00 in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Monday. Finally, LADENBURG THALM/SH SH raised Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a report on Monday, September 16th.

Compass Therapeutics Stock Performance

NASDAQ:CMPX traded down $0.16 during mid-day trading on Friday, reaching $1.43. The stock had a trading volume of 346,663 shares, compared to its average volume of 433,759. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The business has a 50 day simple moving average of $1.76 and a 200 day simple moving average of $1.42. The firm has a market capitalization of $196.75 million, a price-to-earnings ratio of -4.30 and a beta of 0.92.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CMPX. Vanguard Group Inc. grew its holdings in Compass Therapeutics by 1.7% in the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company's stock valued at $8,221,000 after purchasing an additional 71,008 shares during the last quarter. Opaleye Management Inc. purchased a new position in Compass Therapeutics during the 1st quarter valued at about $6,277,000. CM Management LLC raised its position in Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company's stock worth $614,000 after acquiring an additional 185,000 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company's stock valued at $284,000 after purchasing an additional 31,433 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock valued at $141,000 after purchasing an additional 70,200 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.